Q-omics provides the consensus-scored IGKV1D-17 profile across patient tissues and cancer cell-line models. IGKV1D-17 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IGKV1D-17 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, IGKV1D-17 RNA expression shows 6,929 significant pathway-activity associations, with the highest sampling consensus in BRCA. Together, these results highlight HNSC, COAD, and BRCA as cancer lineages where IGKV1D-17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGKV1D-17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGKV1D-17 survival associations across molecular data types. IGKV1D-17 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGKV1D-17 RNA expression–survival associations across cancer types. High IGKV1D-17 expression shows unfavorable associations in ACC, but favorable associations in HNSC, BRCA, SKCM, BLCA and OV. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IGKV1D-17 RNA expression.
This table summarizes IGKV1D-17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for IGKV1D-17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGKV1D-17 shows lower tumor expression in COAD, READ, BRCA and STAD and higher tumor expression in LUAD and KIRC. The COAD box plot shows higher IGKV1D-17 RNA expression in normal versus tumor tissue (log2 FC = −2.152, t-test p < 0.001).
This table shows molecular features associated with IGKV1D-17 in patient tissues and cancer cell lines. In patient samples, IGKV1D-17 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
